Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma

First-line cancer therapies such as alkylating agents and radiation have limited survival benefits for Glioblastoma (GBM) patients. Current research strongly supports the notion that inhibition of aberrant tumor metabolism holds promise as a therapeutic strategy when used in combination with radiati...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Vartanian, Alenoush, Agnihotri, Sameer, Wilson, Mark R., Burrell, Kelly E., Tonge, Peter D., Alamsahebpour, Amir, Jalali, Shahrzad, Taccone, Michael S., Mansouri, Sheila, Golbourn, Brian, Aldape, Kenneth D., Zadeh, Gelareh
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2016
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342495/
https://ncbi.nlm.nih.gov/pubmed/27588472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11680
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak